Literature DB >> 7852952

Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.

C C Ku1, C C King, C Y Lin, H C Hsu, L Y Chen, Y Y Yueh, G J Chang.   

Abstract

Because 21 immunized children (13%) among the 162 confirmed Japanese encephalitis (JE) cases during 1986-1991 occurred in Taiwan, we collected 320 serum samples from Taiwan children aged 15-31 and 27-44 months immediately before the 1st dose (n = 41) and 1-3 months after the 2nd dose (n = 78, 27 pairs), and immediately before (n = 58) and 1-3 months after the 3rd dose (n = 143, 44 pairs) to determine neutralization antibody (Nt Ab) against the Nakayama (N) and Beijing-1 (B) strains and two Taiwan wild type JE viruses (JEV): CC-27 and CH-1392. Our Nt results showed that (1) B vaccine stimulated a better homologous Ab response than N vaccine for Nt Ab seropositivity rate (NASR), produced a higher level of Nt titer after the primary immunization [2 doses = 100% vs. 91%, geometric mean titer (GMT) = 115 vs. 22], had a greater booster effect (3 doses: 100% vs. 95%; GMT = 320 vs 33), and showed a better capability to neutralize two local Taiwan JEV strains, particularly only after 3 doses (ave. NASR for B vs. N = 90% vs. 10%; and GMT for B vs. N = 154 vs. 1); (2) the two wild type JEV strains had different plaque morphology and antigenic variation and the CC-27 strain was not neutralized as well as the CH-1392 strain after 3 doses of vaccine (BBB or NNN or NNB); and (3) 30% of the children had lost JEV Nt Ab one year after the 2nd dose of N vaccine and natural infection with JE virus did occur among those children after immunization. In conclusion, (1) three doses of mouse-brain vaccine are the minimum requirement to protect children against the local Taiwan JEV-, (2) the best strain for a JE vaccine depends on level of Nt Ab it induced, the molecular epidemiology and antigenic variation of the JEV in each local area; and (3) future vaccine must produce better B- and T-cell memory.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852952     DOI: 10.1002/jmv.1890440204

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

1.  Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Authors:  Peter E Nasveld; Joanne Marjason; Sonya Bennett; John Aaskov; Suzanne Elliott; Karen McCarthy; Niranjan Kanesa-Thasan; Emmanuel Feroldi; Mark Reid
Journal:  Hum Vaccin       Date:  2010-11-01

2.  A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.

Authors:  G J Chang; A R Hunt; B Davis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice.

Authors:  Y L Lin; L K Chen; C L Liao; C T Yeh; S H Ma; J L Chen; Y L Huang; S S Chen; H Y Chiang
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 4.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

5.  Accumulation of a 3'-terminal genome fragment in Japanese encephalitis virus-infected mammalian and mosquito cells.

Authors:  Kuo-Chih Lin; Huei-Lan Chang; Ruey-Yi Chang
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice.

Authors:  Zijiang Zhao; Takaji Wakita; Kotaro Yasui
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 7.  Development of a recombinant vaccine against Japanese encephalitis.

Authors:  Rupinderjeet Kaur; Sudhanshu Vrati
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

8.  Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.

Authors:  Yi-Chin Fan; Jo-Mei Chen; Hsien-Chung Chiu; Yi-Ying Chen; Jen-Wei Lin; Chen-Chang Shih; Chih-Ming Chen; Chao-Chin Chang; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

9.  CLEC5A regulates Japanese encephalitis virus-induced neuroinflammation and lethality.

Authors:  Szu-Ting Chen; Ren-Shyan Liu; Ming-Fang Wu; Yi-Ling Lin; Se-Yi Chen; David Tat-Wei Tan; Teh-Ying Chou; I-Shuen Tsai; Lei Li; Shie-Liang Hsieh
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823

10.  Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.

Authors:  Yi-Chin Fan; Hsien-Chung Chiu; Li-Kuang Chen; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2015-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.